Although recent technical advances in thrombectomy have revolutionised acute stroke
treatment, prevalence of disability and death related to stroke remain high. Therefore …

Chronic pain is challenging to treat due to the limited therapeutic options and adverse side-
effects of therapies. Astrocytes are the most abundant glial cells in the central nervous …

Autophagy of mitochondria, termed mitophagy, plays an important role in cerebral ischemia-
reperfusion (IR) injury, but the mechanism is not yet clear. Tissue-type plasminogen activator …

Tissue-type plasminogen activator (tPA) a serine protease is constituted of five functional
domains through which it interacts with different substrates, binding proteins, and receptors …

Ischemic stroke occurs as a result of blood supply interruption to the brain causing tissue
degeneration, patient disabilities or death. Currently, treatment of ischemic stroke is limited …

Axonal injury is a common cause of neurological dysfunction. Unfortunately, in contrast to
axons from the peripheral nervous system, the limited capacity of regeneration of central …

Recombinant tissue plasminogen activator (tPA) is a Food and Drug Administration-
approved thrombolytic treatment for ischemic stroke. tPA is also naturally expressed in glial …

Tissue-type plasminogen activator (t-PA) can modulate permeability of the neurovascular
unit and exacerbate injury in ischemic stroke. We examined the effects of t-PA using in vitro …

In addition to functioning as an activator of fibrinolysis, tissue-type plasminogen activator
(tPA) interacts with neurons and regulates multiple aspects of neuronal cell physiology. In …

Emerging evidence suggests that tissue plasminogen activator (tPA), currently the only FDA-
approved medication for ischemic stroke, exerts important biological actions on the CNS …